143 related articles for article (PubMed ID: 37717927)
1. Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer.
Zhang W; Wang Y; He J; Xu Y; Chen R; Wan X; Shi W; Huang X; Xu L; Wang J; Zha X
Nanomedicine; 2023 Nov; 54():102707. PubMed ID: 37717927
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle albumin-bound paclitaxel is superior to liposomal paclitaxel in the neoadjuvant treatment of breast cancer.
Zhang W; Xu Y; Shi X; Huang X; Chen R; Xu H; Shi W; Wan X; Wang Y; He J; Li C; Wang J; Zha X
Nanomedicine (Lond); 2022 Apr; 17(10):683-694. PubMed ID: 35393861
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer.
Shi W; Wan X; Wang Y; He J; Huang X; Xu Y; Zhang W; Chen R; Wang L; Zheng R; Ma L; Li X; Xu L; Zha X; Wang J
Nanomedicine; 2023 Apr; 49():102666. PubMed ID: 36889422
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis.
Zong Y; Wu J; Shen K
Oncotarget; 2017 Mar; 8(10):17360-17372. PubMed ID: 28061451
[TBL] [Abstract][Full Text] [Related]
6. Retrospective comparisons of nanoparticle albumin-bound paclitaxel and docetaxel neoadjuvant regimens for breast cancer.
Li Y; Chen X; Zhu Q; Chen R; Xu L; Li S; Shi X; Xu H; Xu Y; Zhang W; Huang X; Zha X; Wang J
Nanomedicine (Lond); 2021 Feb; 16(5):391-400. PubMed ID: 33502252
[No Abstract] [Full Text] [Related]
7. Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis.
Liu M; Liu S; Yang L; Wang S
BMC Cancer; 2021 Feb; 21(1):118. PubMed ID: 33541289
[TBL] [Abstract][Full Text] [Related]
8. Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
He F; Liu J; Shen X; Wang Z; Li Q; Li G
Ann Pharmacother; 2022 Aug; 56(8):898-909. PubMed ID: 34963337
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated metastatic breast cancer patients.
Xiong W; Xu T; Liu X; Zhang L; Yuan Y
Cancer; 2024 Apr; 130(S8):1488-1498. PubMed ID: 38271397
[TBL] [Abstract][Full Text] [Related]
10. Nab-paclitaxel-based regimens with docetaxel-based regimens as neoadjuvant treatment for early breast cancer.
Chen Y; Bao B; Lv Y; Sun D; Zhang L; Wang J; Zhao W
Invest New Drugs; 2021 Apr; 39(2):524-529. PubMed ID: 33140143
[TBL] [Abstract][Full Text] [Related]
11. Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis.
Li Y; Lu X; Lin Q; Li W
J Int Med Res; 2020 Aug; 48(8):300060520943473. PubMed ID: 32762463
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis.
Lei L; Chen R; Fan L; Zheng W; Wang X
Ann Palliat Med; 2022 Jul; 11(7):2382-2394. PubMed ID: 35927773
[TBL] [Abstract][Full Text] [Related]
13. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.
Gianni L; Mansutti M; Anton A; Calvo L; Bisagni G; Bermejo B; Semiglazov V; Thill M; Chacon JI; Chan A; Morales S; Alvarez I; Plazaola A; Zambetti M; Redfern AD; Dittrich C; Dent RA; Magazzù D; De Fato R; Valagussa P; Tusquets I
JAMA Oncol; 2018 Mar; 4(3):302-308. PubMed ID: 29327055
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of two-weekly nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy for breast cancer.
Xie F; Chen R; Zhang L; Yin Z; Zhu Q; You S; Jiang C; Li Y; Li S; Zha X; Wang J
Nanomedicine (Lond); 2019 Jun; 14(12):1595-1603. PubMed ID: 30977429
[No Abstract] [Full Text] [Related]
15. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K
Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study.
Shizuku M; Shibata M; Shimizu Y; Takeuchi D; Mizuno Y
Nagoya J Med Sci; 2020 Aug; 82(3):457-467. PubMed ID: 33132430
[TBL] [Abstract][Full Text] [Related]
17. Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2
Kuwayama T; Nakamura S; Hayashi N; Takano T; Tsugawa K; Sato T; Kitani A; Okuyama H; Yamauchi H
Clin Breast Cancer; 2018 Dec; 18(6):474-480. PubMed ID: 30072191
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.
Martín M; Chacón JI; Antón A; Plazaola A; García-Martínez E; Seguí MA; Sánchez-Rovira P; Palacios J; Calvo L; Esteban C; Espinosa E; Barnadas A; Batista N; Guerrero A; Muñoz M; Romio E; Rodríguez-Martín C; Caballero R; Casas MI; Rojo F; Carrasco E; Antolín S
Oncologist; 2017 Nov; 22(11):1301-1308. PubMed ID: 28701571
[TBL] [Abstract][Full Text] [Related]
19. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis.
O'Shaughnessy J; Gradishar WJ; Bhar P; Iglesias J
Breast Cancer Res Treat; 2013 Apr; 138(3):829-37. PubMed ID: 23563958
[TBL] [Abstract][Full Text] [Related]
20. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
Dranitsaris G; Coleman R; Gradishar W
Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]